We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA Addresses Knee Repair Combination Products
U.S. FDA Addresses Knee Repair Combination Products
August 7, 2007
The U.S. Food and Drug Administration (FDA) identifies meaningful clinical trial endpoint measures in new draft guidance on preparing investigational device exemption (IDE) and investigational new drug (IND) applications for combination products used to repair knee cartilage.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor